Pfizer agrees on $340M upfront to buy Therachon for dwarfism drug

Pfizer is set to pay $340 million (€304 million) upfront to buy Therachon for its treatment for a form of short-limbed dwarfism. The deal commits Pfizer to up to $470 million in additional milestones tied to the advance of the early-phase rare disease drug.